Dopamine/glutamate interactions in Parkinson's disease (Q41509241)

1 October 2017

1 reference

title

Dopamine/glutamate interactions in Parkinson's disease (English)

1 reference

1 October 2017

1 reference

2

1 reference

1 October 2017

Lange KW

1

1 reference

PubMed ID

9195597

1 October 2017

Riederer P

series ordinal

3

1 reference

1 October 2017

1 July 1997

1 reference

Neuroscience & Biobehavioral Reviews

1 October 2017

1 reference

1 October 2017

21

1 reference

1 October 2017

393-400

1 reference

1 October 2017

4

1 reference

Neuroleptic malignant syndrome: review and analysis of 115 cases

1 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

The functional anatomy of basal ganglia disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

The role of excitatory amino acids and NMDA receptors in traumatic brain injury

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Autonomic dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

3HMK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Amantadine and the glutamate hypothesis of schizophrenia Experiences in the treatment of neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Behavioural effects and supersensitivity in the rat following intranigral MPTP and MPP+ administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Glutamatergic drugs in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

NEUROLOGICAL DISEASE IN BOXERS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Magnesium gates glutamate-activated channels in mouse central neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Pharmacotoxic psychosis after memantine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Localization of N-methyl-D-aspartate receptors in the rat striatum: effects of specific lesions on the [3H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid binding

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methyl-4-phenylpyridinium: cytochemical and morphological evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism and 1-methyl-4-phenylpyridinium uptake in dissociated cell cultures from the embryonic mesencephalon.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Contralateral disappearance of parkinsonian signs after subthalamic hematoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Elevated NMDA receptors in parkinsonian striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

Beta-N-methylamino-L-alanine neurotoxicity: requirement for bicarbonate as a cofactor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900043-7

7 January 2021

10.1016/S0149-7634(96)00043-7

Identifiers

DOI

1 reference

release_h5gg6465j5fzhcs3dwchqyrdsu

1 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h5gg6465j5fzhcs3dwchqyrdsu

24 November 2022

mapped directly with Wikidata item

PubMed ID

9195597

1 reference

PubMed ID

9195597